X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Advita
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
Relief Therapeutics and AdVita Lifescience are set to enrol the first patient in a Phase II trial of an inhaled formulation of the former’s lead compound, RLF-100 (aviptadil), for preventing Covid-19-related acute respiratory distress syndrome (ARDS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: NeuroRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
According to NeuroRx, across all patients and sites, RLF-100(TM) met the primary endpoint for successful recovery from respiratory failure at days 28 and 60 and also demonstrated a meaningful benefit in survival after controlling for ventilation status and treatment site.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
The objective of the current study is to determine whether RLF-100™, administered at the earlier (severe) stage of COVID-19 can reduce the likelihood of progression to critical COVID-19 with respiratory failure: the predominant cause of death in COVID-19-infected individuals.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: NeuroRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 21, 2020
Details:
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
